Last Updated: October 1, 2026

Aaa Usa Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for AAA USA INC

AAA USA INC has one approved drug.

There are nine US patents protecting AAA USA INC drugs.

Summary for Aaa Usa Inc
US Patents:9
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Aaa Usa Inc

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aaa Usa Inc LUTATHERA lutetium lu 177 dotatate SOLUTION;INTRAVENOUS 208700-001 Jan 26, 2018 RX Yes Yes 12,144,873*PED ⤷  Start Trial Y ⤷  Start Trial
Aaa Usa Inc LUTATHERA lutetium lu 177 dotatate SOLUTION;INTRAVENOUS 208700-001 Jan 26, 2018 RX Yes Yes 12,161,732*PED ⤷  Start Trial Y ⤷  Start Trial
Aaa Usa Inc LUTATHERA lutetium lu 177 dotatate SOLUTION;INTRAVENOUS 208700-001 Jan 26, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Aaa Usa Inc LUTATHERA lutetium lu 177 dotatate SOLUTION;INTRAVENOUS 208700-001 Jan 26, 2018 RX Yes Yes ⤷  Start Trial ⤷  Start Trial
Aaa Usa Inc LUTATHERA lutetium lu 177 dotatate SOLUTION;INTRAVENOUS 208700-001 Jan 26, 2018 RX Yes Yes 10,596,276*PED ⤷  Start Trial Y ⤷  Start Trial
Aaa Usa Inc LUTATHERA lutetium lu 177 dotatate SOLUTION;INTRAVENOUS 208700-001 Jan 26, 2018 RX Yes Yes 12,168,063*PED ⤷  Start Trial Y ⤷  Start Trial
Aaa Usa Inc LUTATHERA lutetium lu 177 dotatate SOLUTION;INTRAVENOUS 208700-001 Jan 26, 2018 RX Yes Yes 12,415,003*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Supplementary Protection Certificates for Aaa Usa Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
4095130 LUC00352 Luxembourg ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212
4095130 23/2024 Austria ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 (MITTEILUNG) 20221212
4095130 CR 2024 00027 Denmark ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130 2490022-7 Sweden ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130 CA 2024 00027 Denmark ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130 122024000038 Germany ⤷  Start Trial PRODUCT NAME: (177LU)LUTETIUMVIPIVOTIDTETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 20221209
4095130 2024C/528 Belgium ⤷  Start Trial PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or Start Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Aaa USA Inc Market Position, Strengths, and Strategic Insights

Last updated: July 24, 2026

Aaa USA Inc’s competitive position can’t be assessed because there is no identifiable drug portfolio, marketed products, active ingredients, FDA registrations, or patent estate to analyze. Without a specific, verifiable product set tied to Aaa USA Inc (e.g., NDC-linked brands, labeled indications, and the company’s US legal entity ownership), any market positioning, IP strength, litigation risk, or generic/biosimilar launch exposure would be fabricated.

What products does Aaa USA Inc market in the US?

No analyzable data.

Which active ingredients and dosage forms are in Aaa USA Inc’s US portfolio?

No analyzable data.

What FDA approval letters or supplements are linked to Aaa USA Inc?

No analyzable data.

How strong is Aaa USA Inc’s patent estate in the US?

No analyzable data.

What patents protect Aaa USA Inc products (composition, formulation, method-of-use)?

No analyzable data.

When do Aaa USA Inc patents expire and when does exclusivity end?

No analyzable data.

What is the Orange Book status of Aaa USA Inc drugs?

No analyzable data.

Which Aaa USA Inc products have listed patents and FDA regulatory exclusivities?

No analyzable data.

Which patents are most likely to be asserted in litigation?

No analyzable data.

How many Paragraph IV challenges exist against Aaa USA Inc products?

No analyzable data.

Which ANDA filers are challenging Aaa USA Inc’s listed patents?

No analyzable data.

What settlement agreements or consent judgments affect Aaa USA Inc exclusivity?

No analyzable data.

What patent litigation affects Aaa USA Inc in the US?

No analyzable data.

Which courts handle Aaa USA Inc cases and what claims were asserted?

No analyzable data.

What is the current procedural posture of Aaa USA Inc disputes?

No analyzable data.

What generic entry risks exist for Aaa USA Inc products?

No analyzable data.

What is the earliest feasible generic or 505(b)(2) entry date?

No analyzable data.

Which manufacturing/IP barriers block generic substitution?

No analyzable data.

How does Aaa USA Inc compare with competitors on product breadth and IP density?

No analyzable data.

Which peer companies sell competing products for the same indications?

No analyzable data.

How does Aaa USA Inc’s portfolio map against likely generic/biosimilar targets?

No analyzable data.

What biologics or biosimilar risks apply to Aaa USA Inc?

No analyzable data.

What BLA/BSUFA pathway items would matter?

No analyzable data.

Which biosimilar filings could trigger litigation windows?

No analyzable data.

What formulations are protected by Aaa USA Inc (if any)?

No analyzable data.

Are there barriers around extended-release, abuse-deterrent, or specialty delivery systems?

No analyzable data.

What licensing deals or partner arrangements impact Aaa USA Inc’s competitive position?

No analyzable data.

Which companies have co-promotion, distribution, or commercialization agreements?

No analyzable data.

What IP is licensed in or out (brands, process, know-how)?

No analyzable data.

Key Takeaways

No analyzable content for Aaa USA Inc without an identified, source-verifiable US product and IP footprint.

FAQs

  1. What NDCs and brands are associated with Aaa USA Inc in FDA datasets?
  2. Which Aaa USA Inc drugs have Orange Book patents listed for each dosage strength?
  3. What are the next milestone dates for ANDA submissions challenging Aaa USA Inc patents?
  4. Which jurisdictions outside the US affect Aaa USA Inc IP enforcement strategy?
  5. Does Aaa USA Inc compete mainly through brand value, distribution, or manufacturing exclusivity?

References (APA)

No citations provided because no verifiable sources were supplied in the request.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links